GSK Infectious Disease Deal History & Licensing Activity
GSK Infectious Disease is a large pharma headquartered in UK. Over the past three years, GSK Infectious Disease has been involved in 2 licensing and acquisition transactions, with a primary focus on Oligonucleotides (2 deals). The company currently has 5 active clinical trials, primarily in Immunology.
Deals (12mo)
3
Active Trials
5
Top Modality
Oligonucleotides
Focus Area
Immunology
GSK Infectious Disease Recent Deal Activity
Licensing, acquisition, and partnership transactions involving GSK Infectious Disease in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Undisclosed | GSK plc | Oligonucleotides | Unknown | license | Feb 2026 |
| HS235 | GSK | Small Molecules | Phase 1 | acquisition | Feb 2026 |
GSK Infectious Disease Pipeline Focus
Therapeutic areas and modalities where GSK Infectious Disease is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
GSK Infectious Disease Strategic Signals
Key indicators of GSK Infectious Disease's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
GSK Infectious Disease Clinical Pipeline
GSK Infectious Disease has 5 active clinical trials across 3 development phases.
2
Phase 1
1
Phase 2
2
Phase 3
See How Your Asset Matches GSK Infectious Disease's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Immunology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Cardiovascular Deal Benchmarks
Market sizing, deal terms, and competitive landscape for cardiovascular
Oligonucleotides Benchmarks
Upfront, milestone, and royalty benchmarks for oligonucleotides deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About GSK Infectious Disease Licensing & Deal Activity
GSK Infectious Disease is a large pharma company based in UK that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, GSK Infectious Disease ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for GSK Infectious Disease include Immunology (2 deals and trials), Cardiovascular (2 deals and trials), and Solid Tumors (2 deals and trials). In terms of modality, GSK Infectious Disease has shown particular interest in oligonucleotides, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for GSK Infectious Disease and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against GSK Infectious Disease's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.